Roivant Plots ‘Streamlined’ Phase III As Ulcerative Colitis Data Raise Blockbuster Potential

The company announced data from the Phase IIb TUSCANY-2 trial of RVT-3101, which is in a tight race with PRA023 from Prometheus, which Merck recently acquired for $10.8bn.

Ulcerative colitis endoscopic biopsy — Roivant announced Phase IIb results for RVT-3101 in ulcerative colitis • Source: Shutterstock

Data from Roivant Sciences Ltd.’s Phase IIb TUSCANY-2 trial of RVT-3101 set the anti-TL1A antibody up as a potential blockbuster treatment for ulcerative colitis amid what looks to become stiff competition with competitor PRA023 from Prometheus Biosciences, Inc, which Merck & Co., Inc. recently acquired.

Following previously disclosed induction phase data from TUSCANY-2, Roivant announced results on 22 June for all-comers as well as those...